Felix Bachmann Selected Research

lisavanbulin

12/2022	Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
1/2021	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
10/2020	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
2/2020	EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.
1/2017	The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
11/2016	The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Felix Bachmann Research Topics

Disease

11	Neoplasms (Cancer) 12/2022 - 08/2002
4	Glioblastoma (Glioblastoma Multiforme) 12/2022 - 11/2016
1	Stomatitis 11/2021
1	Cholangiocarcinoma 11/2021
1	Hand-Foot Syndrome 11/2021
1	Glioma (Gliomas) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Colonic Neoplasms (Colon Cancer) 01/2017
1	Urinary Bladder Neoplasms (Bladder Cancer) 08/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2012
1	Infections 08/2004
1	Iron Overload 08/2004
1	Chronic Hepatitis C 08/2004
1	Neoplasm Metastasis (Metastasis) 11/2002
1	Colorectal Neoplasms (Colorectal Cancer) 11/2002
1	Mastocytoma 08/2002
1	Kaposi Sarcoma (Kaposi's Sarcoma) 03/2002
1	Primary Effusion Lymphoma 03/2002
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2002

Drug/Important Bio-Agent (IBA)

6	lisavanbulinIBA 12/2022 - 11/2016
4	BAL27862IBA 10/2020 - 11/2016
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2002
3	ProdrugsIBA 10/2020 - 11/2016
3	TubulinIBA 02/2020 - 11/2016
2	Pharmaceutical PreparationsIBA 11/2021 - 04/2014
2	Biomarkers (Surrogate Marker)IBA 02/2020 - 11/2016
2	Eukaryotic Initiation Factor-3IBA 08/2014 - 08/2004
1	Retinaldehyde (Retinal)IBA 11/2021
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 11/2021
1	Investigational DrugsIBA 11/2021
1	derazantinibIBA 11/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	tyrosine receptor (receptor, tyrosine)IBA 12/2020
1	Phosphotransferases (Kinase)IBA 12/2020
1	Lysine (L-Lysine)FDA Link 10/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	Epothilones (Epothilone)IBA 01/2017
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017
1	taxaneIBA 01/2017
1	PlatinumIBA 01/2012
1	Tumor Biomarkers (Tumor Markers)IBA 01/2012
1	IronIBA 08/2004
1	Messenger RNA (mRNA)IBA 08/2004
1	Interferon-alpha (Interferon Alfa)IBA 08/2004
1	Fluorouracil (Carac)FDA LinkGeneric 11/2002
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 11/2002
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 11/2002
1	LigandsIBA 08/2002
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2002
1	InterferonsIBA 01/2002

Therapy/Procedure

4	Therapeutics 01/2021 - 11/2016
1	Immunotherapy 01/2021
1	Radiotherapy 01/2017
1	Drug Therapy (Chemotherapy) 01/2012
1	Adjuvant Chemotherapy 11/2002